ATE236981T1 - Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis - Google Patents

Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Info

Publication number
ATE236981T1
ATE236981T1 AT94931000T AT94931000T ATE236981T1 AT E236981 T1 ATE236981 T1 AT E236981T1 AT 94931000 T AT94931000 T AT 94931000T AT 94931000 T AT94931000 T AT 94931000T AT E236981 T1 ATE236981 T1 AT E236981T1
Authority
AT
Austria
Prior art keywords
epiropes
human
hepatitis virus
cell immunodominant
amino acids
Prior art date
Application number
AT94931000T
Other languages
English (en)
Inventor
Geert Leroux-Roels
Robert Deleys
Geert Maertens
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214764&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE236981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE236981T1 publication Critical patent/ATE236981T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/826Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94931000T 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis ATE236981T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93402718 1993-11-04
PCT/EP1994/003555 WO1995012677A2 (en) 1993-11-04 1994-10-28 Immunodominant human t-cell epitopes of hepatitis c virus

Publications (1)

Publication Number Publication Date
ATE236981T1 true ATE236981T1 (de) 2003-04-15

Family

ID=8214764

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99116671T ATE290592T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
AT94931000T ATE236981T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
AT99116672T ATE274578T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99116671T ATE290592T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99116672T ATE274578T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis

Country Status (11)

Country Link
US (4) US6555114B1 (de)
EP (4) EP0992580B1 (de)
JP (2) JPH09504534A (de)
AT (3) ATE290592T1 (de)
AU (1) AU698878B2 (de)
CA (1) CA2175692A1 (de)
DE (3) DE69434295T2 (de)
DK (2) DK0992580T3 (de)
ES (2) ES2239819T3 (de)
PT (2) PT725824E (de)
WO (1) WO1995012677A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
ATE290592T1 (de) * 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE69517521T2 (de) * 1994-04-08 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
WO1999024466A2 (en) * 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
ES2310701T3 (es) 1998-04-17 2009-01-16 Innogenetics N.V. Metodos para mejorar la conformacion de proteinas por medio de agentes reductores.
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
NZ508812A (en) * 1998-06-12 2002-11-26 Aventis Pasteur Peptides for the prevention or treatment of HIV
DE69922958T3 (de) * 1998-06-24 2008-06-26 Innogenetics N.V. Hcv hüllproteine partikel : verwendung für therapeutische impfung
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1105496B1 (de) * 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifizierte hcv peptid-impfstoffe
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ATE502952T1 (de) * 2000-09-01 2011-04-15 Epimmune Inc Hla-bindungspeptide und ihre anwendungszwecke
GB0026094D0 (en) * 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US8129349B2 (en) * 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
MXPA03009632A (es) 2001-04-24 2004-06-30 Innogenetics Nv Proteinas de la envoltura de vhc glucosiladas en la estructura central.
FR2825093B1 (fr) * 2001-05-28 2003-07-18 Bio Merieux Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
FR2825363A1 (fr) * 2001-05-31 2002-12-06 Bio Merieux Polypeptides reagissant avec les anticorps de patients infectes par vhc et utilisations
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc C型肝炎ウイルス特異的細胞障害性t細胞認識エピトープ
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
AU2002361160B2 (en) * 2001-12-18 2008-07-03 Genimmune N.V. Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2003301865A1 (en) * 2002-05-16 2004-06-07 The General Hospital Corporation Epitopes of hepatitis c virus
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
WO2004005473A2 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains
AU2003283365A1 (en) * 2002-11-08 2004-06-07 Innogenetics N.V. HCV vaccine compositions comprising E1 and NS3 peptides
WO2004069864A1 (fr) * 2003-01-07 2004-08-19 Biomerieux Polypeptides f’ du virus de l’hepatite c, epitopes et leurs applications diagnostiques et therapeutiques
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20080112977A1 (en) * 2004-07-03 2008-05-15 Mogam Biotechnology Research Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof
CU23470A1 (es) * 2004-08-11 2009-12-17 Ct Ingenieria Genetica Biotech Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
AU2005292135B2 (en) * 2004-09-29 2011-09-29 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitits C virus
EP2460533A3 (de) 2004-10-18 2014-01-08 Globeimmune, Inc. Therapeutikum auf Hefebasis gegen chronische Hepatitis-C-Infection
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
AU2006301846A1 (en) * 2005-10-13 2007-04-19 Akshaya Bio Inc. Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response
TW200817027A (en) * 2006-06-20 2008-04-16 Metaproteomics Llc Isoalpha acid based protein kinase modulation cancer treatment
WO2008000261A2 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
ES2303496B1 (es) * 2008-02-21 2009-07-07 Fundacion Para El Estudio De Las Hepatitis Virales Metodo analitico perfeccionado para la deteccion de hepatitis c oculta, aplicaciones del mismo y su correspondiente kit de diagnostico.
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン,インコーポレイテッド 慢性c型肝炎ウイルス感染の免疫療法
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
US20120046188A1 (en) * 2009-03-30 2012-02-23 bioMerieux, SA Solid Support for HCV Detection
JP5930967B2 (ja) * 2010-09-08 2016-06-08 学校法人 埼玉医科大学 C型肝炎ウイルスリポソームワクチン
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
CN105073989A (zh) * 2013-02-19 2015-11-18 国立大学法人神户大学 免疫原性多肽表层表达双歧杆菌
EP2970947A4 (de) 2013-03-14 2016-10-12 Abbott Lab Rekombinante hcv-ns3-antigene und mutanten für den verbesserten nachweis von antikörpern
CN105228649B (zh) 2013-03-14 2019-01-18 雅培制药有限公司 Hcv抗原-抗体组合测定和方法以及用在其中的组合物
EP3564384A1 (de) 2013-03-14 2019-11-06 Abbott Laboratories Monoklonale antikörper gegen hcv-core lipid-bindender domäne
US10407508B2 (en) 2013-07-08 2019-09-10 Nanjing Legend Biotech., Ltd. Compositions and methods for increasing protein half-life in a serum
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
AU2019233861A1 (en) * 2018-03-16 2020-10-01 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
US20220090040A1 (en) * 2019-01-25 2022-03-24 Senti Biosciences, Inc. Fusion Constructs for Controlling Protein Function

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
IE911130A1 (en) * 1990-04-04 1991-10-09 Protos Hepatitis c protease inhibitors
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0468657A3 (en) 1990-07-09 1992-02-05 Tonen Corporation Non-a non b hepatitis-specific antigen and its use in hepatitus diagnosis
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
EP0485209A1 (de) 1990-11-08 1992-05-13 Immuno Japan Inc. Mit Non-A Non-B Hepatitis Virus verwandtes Antigen, Aufspürsysteme für Antikörper, Polynukleotide und Polypeptide
AU648912B2 (en) * 1991-06-13 1994-05-05 Dade International Inc. Immunoassay for non-A non-B hepatitis
RU2148587C1 (ru) * 1991-06-24 2000-05-10 Чирон Корпорейшн Полипептид и способ его получения, реагент для иммуноанализа, способ определения присутствия антител и способ индукции иммунного ответа
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
US5428145A (en) 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
AU2513592A (en) * 1991-08-21 1993-03-16 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
PL171489B1 (pl) * 1991-09-13 1997-05-30 Chiron Corp Sposób wytwarzania kompozycji immunogenicznej reagujacej immunologicznie krzyzowo z wieloma izolatami HCV PL
DE69230917T3 (de) * 1991-09-16 2005-04-07 Abbott Laboratories, Abbott Park Verfahren zur detektion von hepatitis c
ATE219522T1 (de) * 1992-02-04 2002-07-15 Chiron Corp Hepatistherapeutikum
US6165730A (en) * 1992-03-06 2000-12-26 N.V. Innogenetics S.A. Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays
KR100235849B1 (ko) * 1993-10-19 1999-12-15 에가시라 구니오 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
ATE290592T1 (de) * 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5543657A (en) * 1994-10-07 1996-08-06 International Business Machines Corporation Single layer leadframe design with groundplane capability

Also Published As

Publication number Publication date
DK0992580T3 (da) 2005-07-11
JPH09504534A (ja) 1997-05-06
PT992580E (pt) 2005-07-29
EP0725824A1 (de) 1996-08-14
EP0992581B2 (de) 2011-05-25
ES2197170T3 (es) 2004-01-01
CA2175692A1 (en) 1995-05-11
US20040047877A1 (en) 2004-03-11
EP0992580A2 (de) 2000-04-12
EP0992580A3 (de) 2000-08-09
EP0979867A3 (de) 2007-06-13
AU7993294A (en) 1995-05-23
DE69433971D1 (de) 2004-09-30
PT725824E (pt) 2003-08-29
EP0992581A2 (de) 2000-04-12
EP0725824B1 (de) 2003-04-09
AU698878B2 (en) 1998-11-12
US6613333B1 (en) 2003-09-02
ATE274578T1 (de) 2004-09-15
ES2239819T3 (es) 2005-10-01
DK0725824T3 (da) 2003-08-11
WO1995012677A2 (en) 1995-05-11
DE69432475D1 (de) 2003-05-15
DE69434295D1 (de) 2005-04-14
US6689368B1 (en) 2004-02-10
EP0979867A2 (de) 2000-02-16
WO1995012677A3 (en) 1995-07-27
JP2004194668A (ja) 2004-07-15
DE69434295T2 (de) 2006-02-16
DE69433971T2 (de) 2005-09-08
EP0992580B1 (de) 2005-03-09
EP0992581A3 (de) 2001-03-07
ATE290592T1 (de) 2005-03-15
US6555114B1 (en) 2003-04-29
DE69432475T2 (de) 2004-03-04
EP0992581B1 (de) 2004-08-25

Similar Documents

Publication Publication Date Title
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
ATE141946T1 (de) Hiv-2-virusvarianten
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
NO892251D0 (no) Fremgangsmaate ved fremstilling av kokkoidosevaksine ved rekombinante teknikker.
DE59209921D1 (de) Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
GB8625435D0 (en) Human apolipoprotein ai
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
ZA89862B (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
DE69534296D1 (de) Sektretierter E1/E2 Hepatitis C Virus-Komplex erhalten aus C-terminal verkürzten Polypeptiden E1 und E2
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
DK0732339T3 (da) Peptider fra HIV-gag-proteinet, fremstilling og anvendelse deraf
DK204588D0 (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
ATE205220T1 (de) Hepatitis-a-impfstoff
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
ATE116336T1 (de) Bakteriozin-peptid.
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
EP0637631A3 (de) Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.
ITFI920071A1 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0725824

Country of ref document: EP

RZN Patent revoked